

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

## **ANNOUNCEMENT ON ESTIMATED GROWTH IN RESULTS FOR THE HALF YEAR OF 2021**

This announcement is made by JOINN Laboratories (China) Co., Ltd. (the “Company”) pursuant to the Inside Information Provisions of the Securities and Futures Ordinance (Cap. 571) (the “SFO”) and the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) under Part XIVA of the Securities and Futures Ordinance (the “SFO”) (the “SFO”) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

### **IMPORTANT NOTICE:**

1. The net profit attributable to the equity holders of the Company will increase by approximately RMB73.559 million, representing a period-on-period increase of approximately 10.5%.

(II) Estimated results

The preliminary estimates made by the Company's finance department are as follows:

1. It is expected that the net profit attributable to the shareholders of the Company for the period from January to June 2021 will be approximately RMB149.2238 million to RMB158.2461 million, representing an increase of approximately RMB73.559 million to RMB82.5813 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 97.2% to 109.1%.
2. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the period from January to June 2021 will increase by approximately RMB60.9059 million to RMB69.9283 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 95.0% to 109.1%.
3. It is expected that the net profit attributable to the shareholders of the Company for the period from January to June 2021 will increase by approximately RMB59.0003 million to RMB68.0226 million as compared with the data in the restated financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 65.4% to 75.4%.
4. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the period from January to June 2021 will increase by approximately RMB46.3473 million to RMB55.3696 million as compared with the restated financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 58.9% to 70.4%.
5. It is expected that the revenue from January to June 2021 will increase by approximately RMB117.3337 million to RMB157.0692 million as compared with the data in the financial statements for the corresponding period of last year, representing a period-on-period increase of approximately 29.5% to 39.5%.

(III) The estimated results have not been audited by certified public accountants.

## **II. RESULTS FOR THE CORRESPONDING PERIOD OF LAST YEAR**

- (I) Net profit attributable to shareholders of the Company for the corresponding period of last year: RMB75.6648 million. Net profit attributable to shareholders of the Company after deducting non-recurring profit or loss: RMB64.1024 million; earnings per share: RMB0.34.
- (II) Restated net profit attributable to shareholders of the Company for the corresponding period of last year: RMB90.2235 million; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses: RMB78.6611 million.
- (III) Revenue realized for the corresponding period of last year was RMB397.355 million.

## **III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS DURING THE PERIOD**

- (I) Impact of principal business. With extensive experience in evaluation of innovative drugs and good reputation accumulated in the industry, the Company continued to maintain rapid growth in order intake in the first half of 2021. At the same time, the Company explored the room of capacity to the greatest extent through reasonable arrangement of test projects, which further improved the utilization rate of facilities. The execution and completion of domestic safety evaluation orders were higher than that of the corresponding period of last year, showing a significant sizable effect.
- (II) Impact of non-operating profit or loss. It was mainly due to (i) the government

#### IV. RISK WARNING

There are no material uncertainties affecting the accuracy of the estimated results.

#### V. OTHER EXPLANATIONS

The financial data contained in this results forecast is prepared in accordance with the China Accounting Standards for Business Enterprises and the estimated data is only preliminary accounting figures. The specific and accurate financial data shall refer to the unaudited 2021 interim results announcement and the 2021 Interim Report prepared in accordance with the China Accounting Standards for Business Enterprises or the International Financial Reporting Standards officially disclosed by the Company. Investors are advised to pay attention to investment risks.

By Order of the Board  
JOINN Lab, a tie (Chi a) C., L d.

Chairperson

Hong Kong, August 9, 2021

*As at the date of this announcement, the Board consists of Mr. WANG Yuxia as the Chairperson and executive Director, Mr. SUN Mingcheng, Ms. SUN Yunxia and Dr. YAO Dalin as executive Directors, Mr. ZHANG Fan as non-executive Director, and Mr. SUN Mingcheng, Dr. ZHANG Fan and Mr. ZHANG Fan as independent non-executive Directors.*